Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
4.880
+0.090 (1.88%)
At close: May 16, 2025, 4:00 PM
4.720
-0.160 (-3.28%)
After-hours: May 16, 2025, 7:59 PM EDT
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Xeris Biopharma Holdings stock ranges from a low of $4.00 to a high of $8.00. The average analyst price target of $6.25 forecasts a 28.07% increase in the stock price over the next year.
Price Target: $6.25 (+28.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $6 → $7 | Buy | Maintains | $6 → $7 | +43.44% | May 9, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $5 → $6 | Buy | Maintains | $5 → $6 | +22.95% | Mar 7, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $5 → $6.5 | Strong Buy | Maintains | $5 → $6.5 | +33.20% | Mar 7, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $3 → $4 | Hold | Reiterates | $3 → $4 | -18.03% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.6 → $8 | Strong Buy | Reiterates | $6.6 → $8 | +63.93% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
272.04M
from 203.07M
Increased by 33.96%
Revenue Next Year
326.10M
from 272.04M
Increased by 19.87%
EPS This Year
-0.08
from -0.37
EPS Next Year
0.10
from -0.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 284.1M | 357.6M | 434.6M | ||
| Avg | 272.0M | 326.1M | 381.2M | ||
| Low | 257.7M | 294.5M | 337.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.9% | 31.5% | 33.3% | ||
| Avg | 34.0% | 19.9% | 16.9% | ||
| Low | 26.9% | 8.3% | 3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.12 | 0.25 | 0.50 |
| Avg | -0.08 | 0.10 | 0.37 |
| Low | -0.18 | -0.15 | 0.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 386.0% |
| Avg | - | - | 252.1% |
| Low | - | - | 98.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.